192 related articles for article (PubMed ID: 18175773)
21. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): response to Server et al.
Tseng KH
Diabetes Care; 2005 Oct; 28(10):2595; author reply 2595-6. PubMed ID: 16186315
[No Abstract] [Full Text] [Related]
22. ASCOT-LLA: questions about the benefits of atorvastatin.
Drummond GA
Lancet; 2003 Jun; 361(9373):1987-8. PubMed ID: 12801765
[No Abstract] [Full Text] [Related]
23. Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study.
Kaasenbrood L; Poulter NR; Sever PS; Colhoun HM; Livingstone SJ; Boekholdt SM; Pressel SL; Davis BR; van der Graaf Y; Visseren FL;
Circ Cardiovasc Qual Outcomes; 2016 May; 9(3):213-21. PubMed ID: 27174798
[TBL] [Abstract][Full Text] [Related]
24. [Statin therapy for hypertensive patients].
Svilaas A; Kjeldsen S; Midtbø K; Westheim A; Syvertsen JO
Tidsskr Nor Laegeforen; 2004 Jan; 124(2):165-6. PubMed ID: 14743227
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm.
Sever PS; Poulter NR; Chang CL; Thom SA; Hughes AD; Welsh P; Sattar N;
J Am Coll Cardiol; 2013 Aug; 62(8):717-29. PubMed ID: 23948514
[TBL] [Abstract][Full Text] [Related]
26. Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study.
Williams B; Lacy PS; Cruickshank JK; Collier D; Hughes AD; Stanton A; Thom S; Thurston H;
Circulation; 2009 Jan; 119(1):53-61. PubMed ID: 19103995
[TBL] [Abstract][Full Text] [Related]
27. Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.
Plosker GL; Lyseng-Williamson KA
Pharmacoeconomics; 2007; 25(12):1031-53. PubMed ID: 18047388
[TBL] [Abstract][Full Text] [Related]
28. The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1.
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
Pharmacoeconomics; 2009; 27(3):221-30. PubMed ID: 19354342
[TBL] [Abstract][Full Text] [Related]
29. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH;
Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833
[TBL] [Abstract][Full Text] [Related]
30. Statins to prevent cardiovascular events in hypertensive patients. The ASCOT-LLA study.
Osende JI; Ruiz-Ortega M; Blanco-Colio LM; Egido J
Nephrol Dial Transplant; 2004 Mar; 19(3):528-31. PubMed ID: 14767002
[No Abstract] [Full Text] [Related]
31. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
Schwartz GG; Olsson AG; Ezekowitz MD; Ganz P; Oliver MF; Waters D; Zeiher A; Chaitman BR; Leslie S; Stern T;
JAMA; 2001 Apr; 285(13):1711-8. PubMed ID: 11277825
[TBL] [Abstract][Full Text] [Related]
32. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
[TBL] [Abstract][Full Text] [Related]
33. Is plasma renin activity a biomarker for the prediction of renal and cardiovascular outcomes in treated hypertensive patients? Observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Sever PS; Chang CL; Prescott MF; Gupta A; Poulter NR; Whitehouse A; Scanlon M
Eur Heart J; 2012 Dec; 33(23):2970-9. PubMed ID: 22942337
[TBL] [Abstract][Full Text] [Related]
34. Lipid lowering in hypertension and heart protection: observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) and the Heart Protection Study.
Nadar S; Lim HS; Beevers DG; Lip GY
J Hum Hypertens; 2002 Dec; 16(12):815-7. PubMed ID: 12522461
[No Abstract] [Full Text] [Related]
35. Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial.
Bangalore S; Fayyad R; Laskey R; DeMicco D; Deedwania P; Kostis JB; Messerli FH;
Eur Heart J; 2014 Jul; 35(27):1801-8. PubMed ID: 23990605
[TBL] [Abstract][Full Text] [Related]
36. [Clinical study of the month. Premature interruption of ASCOT and CARDS clinical trials of cardiovascular prevention with atorvastatin in patients with arterial hypertension or diabetes mellitus: compromise between ethics and statistics in evidence-based medicine ].
Scheen AJ
Rev Med Liege; 2003 Sep; 58(9):585-90. PubMed ID: 14626655
[TBL] [Abstract][Full Text] [Related]
37. ASCOT-LLA: questions about the benefits of atorvastatin.
Devroey D; Ginst LV
Lancet; 2003 Jun; 361(9373):1985-6; author reply 1986-7. PubMed ID: 12801760
[No Abstract] [Full Text] [Related]
38. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
Dahlöf B; Sever PS; Poulter NR; Wedel H; Beevers DG; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
Lancet; 2005 Sep 10-16; 366(9489):895-906. PubMed ID: 16154016
[TBL] [Abstract][Full Text] [Related]
39. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Szarek M; Tsai J;
JAMA; 2005 Nov; 294(19):2437-45. PubMed ID: 16287954
[TBL] [Abstract][Full Text] [Related]
40. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.
Deedwania P; Barter P; Carmena R; Fruchart JC; Grundy SM; Haffner S; Kastelein JJ; LaRosa JC; Schachner H; Shepherd J; Waters DD;
Lancet; 2006 Sep; 368(9539):919-28. PubMed ID: 16962881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
